CML Publications of the Month
As part of our monthly news service we would like to make you aware of important CML publications. From the many papers published in September, Professor Timothy Hughes has selected topical, interesting papers for your perusal. Papers with a clinical, scientific and low and middle income country focus are shared.
October 2026
Clinical CML papers
Predictive biomarkers of sustained treatment-free remission in chronic myeloid leukemia: gene expression analysis from the ENESTfreedom and ENESTop studies
Radich J et al. Haematologica, October 2026
– open access publication
Real-world outcomes of asciminib versus first- and second-generation tyrosine kinase inhibitors as second-line treatment for chronic-phase chronic myeloid leukemia
Atallah EL et al. Leuk Res, October 2026
(epub ahead of print)
Adapting UK clinical practice in chronic myeloid leukemia chronic phase to contemporary management recommendations: The ADAPT 2.0 Study
Milojkovic D et al. Eur J Haematol, October 2026 – open access publication
Comparative outcomes of generic and branded dasatinib in chronic-phase chronic myeloid leukemia: A single-center within-patient analysis
Babiker A et al. J Blood Med, October 2026 – open access publication
Exploring the potential of vamotinib in Ph+ leukemias: Is it indeed a 3rd generation tyrosine kinase inhibitor?
Lucini C et al. J Hematol Oncol, October 2026 – open access publication
Sequential TKI treatment in patients with chronic phase chronic myeloid leukemia resistant to frontline nilotinib or dasatinib therapy. A real-life survey from the Italian Campus CML Network
Gugliotta G et al. Clin Lymphoma Myeloma Leuk, October 2026 – open access publication
Rethinking cardiovascular risk stratification in TKI-treated chronic myeloid leukemia
Cordeanu EM et al. Cancer Treat Res Commun, October 2026
(epub ahead of print) – open access publication
The evolving landscape of tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia:
A 25-year journey
Haddad FG et al. Blood Rev, October 2026 (epub ahead of print)
Chronic myeloid leukemia in a global context: confirmatory findings and novel discoveries from a refined Japanese cohort
Fujita M et al. Leukemia, October 2026 (epub ahead of print)
Current perspectives on high-risk genomic profiles in chronic myeloid leukemia: from bench to clinical
Sharif MI et al. Int J Hematol, October 2026
Successful pregnancy after planned pregnancy-oriented TKI interruption and embryo transfer following ponatinib re-consolidation in chronic phase chronic myeloid leukemia
Takagi F et al. EJHaem Oct 2026 (epub ahead of print) – open access publication
Tyrosine kinase inhibitor use and risk of neurodegenerative disease:
A Swedish population-based cohort study
Wittström F et al. Alzheimers Dement, October 2026 – open access publication
Tyrosine kinase inhibitor (second-generation)-related pancreatic toxicity in chronic myeloid leukemia patients analyzed using the FAERS database
Wang S et al. Int J Clin Pharmacol Ther, October 2026 (epub ahead of print)
Next-generation polymerase chain reaction assay for BCR::ABL1 in CML: Comprehensive validation for standardized measurable residual disease detection
Kim YH et al. Blood Res, October 2026 – open access publication
Scientific CML papers
A design approach for bitopic kinase inhinbitors
Stevenson JW et al. Nature, September 2026 – open access publication
Prominin-1 (CE133) is essential for the determination of the phenotype of Philadelphia chromosome-positive leukemias
Metodieva A et al. Exp Hematol, Oct 2026 (epub ahead of print) – open access publication
RUNX1 aberrations in blast-phase chronic myeloid leukemia induce the RNA-binding protein SPAT2L, which promotes growth, survival and stress granulate assembly
Palmer DA et al. Leukemia, October 2026 (epub ahead of print) – open access publication
Targeting the eIF4F translation initiation complex disrupts BCR::ABL1 translation and overcomes drug resistance in CML
Yen R et al. Leukemia, October 2026 (epub ahead of print)
Pediatric CML papers
A rare BCR::SPECC1L::ABL1 fusion in a pediatric chronic myeloid leukemia patient
Cubuk E et al. J Pediatr Hematol Oncol, October 2026
LMIC CML papers
Twenty-five years of chronic myeloid leukemia therapy in India: A model for precision oncology in a resource-constrained setting
Chaukan P et al. Clin Lymphoma Myeloma Leuk, October 2026 (epub ahead of print)